Name of organisation
1) Department/Research groupPharmacoEpidemiology Unit
2) Organisation/affiliationClaude Bernard Lyon 1 University
Short Name in the inventoryPELyon
Administrative Contact
Title Dr
Last name VAN GANSE
First name Eric
Address line 1Unité de Pharmacoépidémiologie
Address line 2Faculte d'Odontologie Universite Lyon 1
Address line 311 rue Guillaume Paradin
CityLyon cedex 08
PostcodeF-69372
CountryFrance
Phone number (incl. country code)33-478778645
Alternative phone number
Fax number (incl. country code)33-478778660
Scientific Contact
Title Dr
Last name VAN GANSE
First name Eric
Address line 1Unité de Pharmacoépidémiologie
Address line 2Faculte d'Odontologie Universite Lyon 1
Address line 311 rue Guillaume Paradin
CityLyon cedex 08
PostcodeF-69372
CountryFrance
Phone number (incl. country code)33-478778610
Alternative phone number
Fax number (incl. country code)33-478778660
Alternative Scientific Contact
Title Miss
Last name BELHASSEN
First name Manon
Address line 1Unité de Pharmacoépidémiologie
Address line 211 rue Guillaume Paradin
Address line 3
CityLyon Cedex 08
PostcodeF-69372
CountryFrance
Phone number (incl. country code)33-478785701
Alternative phone number
Fax number (incl. country code)
2. Description
Main research areas :
- drug utilisation in relation to target populations or recommendations
- compliance
- efficacy of drugs in real life settings (effectiveness)
- safety of drugs in real life settings
- burden of disease (unmet needs)
Areas of expertise :
- respiratory diseases (asthma, COPD)
- endocrinology (lipids, obesity, diabetes)
- neurology (MS)
- public health, burden of disease and health economics
Research tools :
- public databases (Health Insurance claims databases)
. National sample of beneficiaries (about 1% of the French population)
. Regional database (Rhône-Alpes region)
- private databases (Cegedim Strategic Data)
. CSD French database (GPs and specialists)
. CSD international databases (GPs)
- patient reported outcomes (PROs). Patients interviewed about their perception of disease and/or therapy, or on confounding factors (e.g. smoking, diet)
3. Category
University based
Hospital based
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
No
Statistician
Yes
No
Clinician
No
Yes
Clinical Pharmacologist
Yes
No
Pharmacist
No
Yes
IT specialist
No
Yes
Ethics expertise
No
Yes
Legal expertise
No
Yes
Regulatory expertise
No
Yes
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Disorders of the central nervous system
Ear, nose and oropharynx disorders
Endocrine disorders
Geriatrics
Gynaecology
Immunological products and vaccines
Immunosuppression
Nutrition and blood
Paediatrics
Psychiatry
Renal impairment
Respiratory diseases
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Surveys
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Between 150 and 1499
Between 1500 and 14999
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
No
In the community
Yes
Electronic data capture systems
Yes
System used:
EHRs
Interactive voice response systems
No
Call centre
No
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Electronic Health Records (EHRs)3
Claims databases15
11. Registries established by centre
Drug RegistryNatalizumab
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Networks registered with ENCePP
EuroDURG
Respiratory Effectiveness Group (REG)
Other networks:
Network nameNationalInternationalLink to webpage